Chris Ogden
Vermögen: 461 070 $ am 31.05.2026
Vermögen: 461 070 $ am 31.05.2026
Chris Ogden is currently Chief Financial Officer, Secretary & Senior VP at CytomX Therapeutics, Inc. since 2021.
Former roles include Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Education includes an undergraduate degree from Wabash College and an MBA from Harvard Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.06.2026 | 128.075 ( 0,06 % ) | 461 070 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Finanzdirektor/CFO | 21.09.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Finanzdirektor/CFO | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Wabash College
Wabash College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen